Thermo Fisher reported 2025 revenue of $44.6 billion and Q1 2026 revenue of $11.0 billion. The thesis depends on biopharma demand, instrument and consumables mix, diagnostics normalization, margin durability, M&A integration and cash conversion.
Thermo Fisher: the lab-tools compounder still has to prove the biopharma cycle is healing
NYSETMOCoverage BootstrapThermo Fisher Scientific Inc.
Thesis summary
Thermo Fisher reported 2025 revenue of $44.6 billion and Q1 2026 revenue of $11.0 billion. The thesis depends on biopharma demand, instrument and consumables mix, diagnostics normalization, margin durability, M&A integration and cash conversion.
View article
Discuss the thesis
0 commentsCommenting requires active membershipBecome a member
Attack the thesis, not the person.Add evidence when challenging claims.No pump, spam, or low-effort comments.
No comments yet. Start the discussion with evidence, a question, or a bear case.